Samsung Biologics, cumulative order amt exceeded 2 trillion

Signed a 500 billion won main contract with Novartis following the Pfizer contract

Secured in the first half of the year similar to the total amount of orders received last year

Panoramic view of Samsung Biologics

Samsung Biologics announced on the 10th that it has signed a main contract for biopharmaceutical consignment manufacturing (CMO) worth 511.1 billion won from global pharmaceutical company Novartis.

 

Through this contract, the cumulative amount of orders received this year increased to 2.3387 trillion won.

 

This contract with Novartis was signed one year after the letter of intent (LOI) of 100 billion won in June last year.

 

Samsung Biologics and Novartis signed a main contract with a size that is five times larger than the previous LOI.

 

Samsung Biologics signed a CMO contract worth 1.2 trillion won with global pharmaceutical company Pfizer on the 4th before signing a large-scale contract with Novartis.

 

The amount of orders received from Pfizer and Novartis alone amounts to 1.7 trillion won.

 

This is similar to last year's total order amount of 1.7835 trillion won.

 

Samsung Biologics is increasing large-scale, long-term contracts while securing major global big pharma customers.

 

It has secured 13 of the top 20 global pharmas as customers.

 

Samsung Biologics is strengthening its ability to win orders based on its competitiveness in the global No.

 

1 production capacity (CAPA), speed, and quality.

 

Samsung Biologics started with the 30,000-liter plant 1 in 2011 and expanded the 154,000-liter plant 2 in 2013.

 

In 2015, a third plant with a capacity of 180,000 liters was built.

 

Starting in 2020, construction began on the 240,000-liter class 4 plant, the world's largest single plant, and began full operation last month.

 

The total production capacity is 604,000 liters.

 

Samsung Biologics started construction of its 5th plant in April to preemptively respond to the market's demand for biopharmaceutical CMO.

 

Completion is targeted for April 2025.

 

When completed, the total production capacity will be 784,000 liters.

 

Through process innovation, Samsung Biologics has shortened the technology transfer period, which is essential for biopharmaceutical production, to three months, half of the industry average.

 

Process optimization was carried out through a specialized technology transfer team.

 

The deployment success rate of Samsung Biologics is over 98%.

 

A batch refers to a biopharmaceutical production unit.

 

The cumulative number of regulatory approvals was 231.

 

Samsung Biologics is strengthening its capabilities to respond to the demand for next-generation drugs such as antibody-drug conjugates (ADCs).

 

In April of this year, it invested in Araris Biotech, an ADC treatment technology development company, through the Life Science Fund.

 

It also plans to have an ADC production facility by 2024.

 

Samsung Biologics plans to actively respond to the blockbuster drug market, such as Alzheimer's treatment.

 

Based on the world's largest production capacity, it plans to expand orders by focusing on products that require mass production and products that newly expand indications.

 

It plans to win orders for the 5th plant targeting Alzheimer's treatment, which has a lot of unmet demand.

 

An official from Samsung Biologics said, "We have expanded our global bases, mainly in North America, to narrow the physical distance with our customers and provide prompt services." "We opened a sales office in New Jersey in March of this year following San Francisco in October 2020 to provide services to global customers," he said.